# First in Human Study of T3P-Y058-739 (T3P)

Source: https://onco.cc/trials/nct05120596/  
OnCo record `nct05120596` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Pembrolizumab in advanced solid tumours, run by T3 Pharmaceuticals AG, now recruiting.

## Summary

First in Human Study of T3P-Y058-739 (T3P) is a phase 1/2 interventional study registered as NCT05120596 by T3 Pharmaceuticals AG, with 100 participants planned, started 2022-04-26 and due to reach its primary completion in 2027-02-28. Interventions recorded: Pembrolizumab+T3P-Y058-739, T3P-Y058-739 (IV) and T3P-Y058-739 (IT).

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05120596
- Phase: 1/2
- Setting: An Open-label, Phase I/II Study of T3P-Y058-739, a Genetically-modified Strain of the Bacterium Yersinia Enterocolitica, in Patients With Advanced Solid Tumours
- Sponsor: T3 Pharmaceuticals AG
- Enrolled: 100

## Sources

- ClinicalTrials.gov NCT05120596: https://clinicaltrials.gov/study/NCT05120596

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)

---
JSON: https://onco.cc/api/v1/entities/nct05120596.json